Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ergomed plc
The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.
Appointments: IFPMA, German Merck, Ergomed, Spectrum, Astellas, Laboratoris Sanifit and Audentes Therapeutics
Appointment announcements this week include Greg Perry becoming the IFPMA’s new assistant director general, a new head of corporate affairs at German Merck, new CEOs at Ergomed and Spectrum, and other senior hires at Astella Americas, Laboratoris Sanifit, and a new board member at Audentes Therapeutics Inc.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The biggest Phase III trial in head and neck cancer is resuming after the FDA lifted a freeze on trials evaluating CEL-SCI's lead asset Multikine in the indication, giving a boost to its commercial prospects.
- Contract Research, Toxicology Testing-CRO
- Other Names / Subsidiaries
- Ashfield Pharmacovigilance
- Ergomed Group
- Haemostatix Limited
- PSR Group BV